OBJECTIVES: Bacille Calmette-Guerin (BCG), a live attenuated Mycobacterium bovis vaccine, poses a risk to human immunodeficiency virus (HIV)-infected children; this risk has not been well quantified. We estimate the risk of disseminated BCG disease in HIV-infected children in a setting highly endemic for tuberculosis and HIV. DESIGN AND METHODS: We conducted a prospective hospital-based surveillance study in the Western Cape Province, South Africa. Clinical and laboratory-confirmed cases of disseminated BCG disease in children<1 year of age from January 2002 to December 2004 at a referral hospital were used as numerator data. Denominator data for calculations of disseminated BCG risk were obtained through estimating the total number of HIV-infected infants receiving BCG based on the known vaccination coverage in the study setting, combined with population data on the total number of children<1 year of age, the known HIV prevalence amongst women attending public antenatal care facilities and different scenarios (5-15%) for the rate of vertical HIV transmission. RESULTS: Nine cases of disseminated BCG disease were identified over the study period, seven of these were in HIV-infected infants. The estimated risk for HIV-infected infants to develop disseminated BCG disease, given a 95% BCG coverage and an HIV prevalence of 12.4-15.4% amongst women, were as follows for different scenarios of vertical HIV transmission: 329-417/100,000 vaccinees (assuming 5% vertical HIV transmission), 164-208/100,000 vaccinees (assuming 10% vertical HIV transmission) and 110-139/100,000 vaccinees (assuming 15% vertical HIV transmission). CONCLUSIONS: The risk of disseminated BCG disease is increased several hundred fold in HIV-infected infants compared to the documented risk in HIV-uninfected infants. Data on the protective effect of BCG in HIV-exposed and infected children is lacking. Population- and hospital-based surveillance is vitally important to more accurately estimate the safety and benefits of BCG in HIV-exposed and infected infants.
OBJECTIVES: Bacille Calmette-Guerin (BCG), a live attenuated Mycobacterium bovis vaccine, poses a risk to human immunodeficiency virus (HIV)-infectedchildren; this risk has not been well quantified. We estimate the risk of disseminated BCG disease in HIV-infectedchildren in a setting highly endemic for tuberculosis and HIV. DESIGN AND METHODS: We conducted a prospective hospital-based surveillance study in the Western Cape Province, South Africa. Clinical and laboratory-confirmed cases of disseminated BCG disease in children<1 year of age from January 2002 to December 2004 at a referral hospital were used as numerator data. Denominator data for calculations of disseminated BCG risk were obtained through estimating the total number of HIV-infectedinfants receiving BCG based on the known vaccination coverage in the study setting, combined with population data on the total number of children<1 year of age, the known HIV prevalence amongst women attending public antenatal care facilities and different scenarios (5-15%) for the rate of vertical HIV transmission. RESULTS: Nine cases of disseminated BCG disease were identified over the study period, seven of these were in HIV-infectedinfants. The estimated risk for HIV-infectedinfants to develop disseminated BCG disease, given a 95% BCG coverage and an HIV prevalence of 12.4-15.4% amongst women, were as follows for different scenarios of vertical HIV transmission: 329-417/100,000 vaccinees (assuming 5% vertical HIV transmission), 164-208/100,000 vaccinees (assuming 10% vertical HIV transmission) and 110-139/100,000 vaccinees (assuming 15% vertical HIV transmission). CONCLUSIONS: The risk of disseminated BCG disease is increased several hundred fold in HIV-infectedinfants compared to the documented risk in HIV-uninfectedinfants. Data on the protective effect of BCG in HIV-exposed and infected children is lacking. Population- and hospital-based surveillance is vitally important to more accurately estimate the safety and benefits of BCG in HIV-exposed and infected infants.
Authors: N Pavan Kumar; R Anuradha; R Suresh; R Ganesh; Janani Shankar; V Kumaraswami; Thomas B Nutman; Subash Babu Journal: Clin Vaccine Immunol Date: 2011-09-28
Authors: W Brittle; B J Marais; A C Hesseling; H S Schaaf; M Kidd; E Wasserman; T Botha Journal: J Clin Microbiol Date: 2009-03-11 Impact factor: 5.948
Authors: Nicole Ritz; Marc Tebruegge; Tom G Connell; Aina Sievers; Roy Robins-Browne; Nigel Curtis Journal: Antimicrob Agents Chemother Date: 2008-10-27 Impact factor: 5.191
Authors: Hillarie Plessner Windish; Malcolm S Duthie; Ayesha Misquith; Greg Ireton; Elyse Lucas; John D Laurance; Remy H Bailor; Rhea N Coler; Steven G Reed Journal: Vaccine Date: 2011-08-02 Impact factor: 3.641
Authors: Kara Jensen; Myra Grace Dela Pena; Robert L Wilson; Uma Devi K Ranganathan; William R Jacobs; Glenn Fennelly; Michelle Larsen; Koen K A Van Rompay; Pamela A Kozlowski; Kristina Abel Journal: Trials Vaccinol Date: 2013-11-01
Authors: Nazma Mansoor; Thomas J Scriba; Marwou de Kock; Michele Tameris; Brian Abel; Alana Keyser; Francesca Little; Andreia Soares; Sebastian Gelderbloem; Silvia Mlenjeni; Lea Denation; Anthony Hawkridge; W Henry Boom; Gilla Kaplan; Gregory D Hussey; Willem A Hanekom Journal: J Infect Dis Date: 2009-04-01 Impact factor: 5.226